Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Crit Rev Oncol Hematol. 2017 Mar 14;113:71–78. doi: 10.1016/j.critrevonc.2017.03.011

Figure 1.

Figure 1

Kallistatin inhibits the migration and invasion of prostate cancer cells. Kallistatin (1 μM) prevented tissue kallikrein (TK, 0.1 μM)-induced (A) migration and (B) invasion of DU-145 prostate cancer cells. Wild-type kallistatin (KS, 1 μM), but not heparin-binding site mutant kallistatin (HMKS, 1 μM), antagonized epidermal growth factor (EGF, 1 ng/ml)-induced (C) migration and (D) invasion of DU-145 prostate cancer cells, indicating that kallistatin’s effects are mediated via its heparin-binding domain. n=3, *P<0.05 vs. other groups.